HBD-2 vs Pidotimod
Head-to-head comparison of HBD-2 (Human Beta-Defensin 2) and Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) — benefits, dosing, side effects, research data, and where to buy.
| Property | HBD-2 | Pidotimod |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Human Beta-Defensin 2 | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid |
| Molecular Weight | 4316 Da | 244.27 Da |
| Half-Life | Minutes to hours; protease-sensitive | 3-4 h |
| Amino Acids | 41 | 2 |
| Typical Dose | Research use only; no approved human dose | 400-800 mg/day |
| Route | Topical / Intranasal / Research parenteral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 420 | 200 |
| Research Status | Pre-clinical | Clinical |
HBD-2 Benefits
- ✓broad-spectrum antimicrobial activity
- ✓epithelial barrier defense
- ✓innate immune modulation
- ✓anti-biofilm potential
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
HBD-2 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
HBD-2 Side Effects
- ⚠local irritation at high concentrations
- ⚠proteolytic instability
- ⚠potential pro-inflammatory signaling
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
Research Overview
HBD-2
Human beta-defensin 2 has been studied extensively for direct microbicidal effects and for its role in shaping mucosal immunity. Preclinical work shows activity against Gram-negative and Gram-positive organisms, with additional effects on leukocyte recruitment and wound defense.
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.